S
Stelexis Therapeutics
Stelexis Therapeutics is a cancer therapeutics company
About Stelexis Therapeutics
Stelexis Therapeutics is a biotechnology startup that focuses on revolutionizing cancer treatment. The company operates in the healthcare sector, specifically in the field of oncology. It primarily serves patients suffering from cancer, with a particular focus on those who have experienced cancer progression and relapse.
The company's business model revolves around the discovery and development of novel treatments targeting cancerous stem cells, which are often the root cause of cancer progression and relapse. These cells are typically resistant to current treatment methods, making them a challenging but crucial target for effective cancer therapy.
Stelexis has developed a proprietary platform, TumorOrigin™, which allows for the unprecedented study of these cancerous stem cells. This platform uses large banks of patient-derived samples to isolate and expand these rare cells, overcoming previous limitations such as insufficient cell count and cell survival. The TumorOrigin™ platform is designed to discover new, druggable targets on these cells, opening up new avenues for drug discovery and development.
The company generates revenue through the development and commercialization of these novel cancer treatments. Currently, Stelexis is advancing two lead candidates, STLX1018 and STLX2012, into clinical development. These candidates target the elimination of cancerous stem cells in Acute Myeloid Leukemia (AML) and solid tumors.
In summary, Stelexis Therapeutics is a pioneering biotech startup that aims to transform cancer treatment by targeting the root cause of the disease - cancerous stem cells. The company's innovative TumorOrigin™ platform is set to revolutionize the field of oncology, offering hope to countless patients worldwide.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- New York City, United States
- Employees
- 17
- Open positions
- None listed
- Dealroom signal
- 43.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2019 | $43M | $172M | Undisclosed | — |
| SPINOUT✓Other financing | Jan 2017 | $0 | — | Albert Einstein College of Medicine · Harvard Medical School | — |
Growth signals
Latest recorded traffic for Stelexis Therapeutics is 2.9K monthly website visits, up 190% over the last three months. Stelexis Therapeutics's team grew 13.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Deerfield
Other known investors2 additional known investors
Albert Einstein College of Medicine
Harvard Medical School
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Stelexis Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Stelexis Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.